Dyslipidemia is a well-known risk factor for the development and progression of CV diseases.5???7 In addition to the well-characterized proatherosclerotic effect of high low-density lipoprotein cholesterol (LDL-C) concentrations, there is growing evidence in support of an independent association between incident CV diseases and metabolic dyslipidemia (MD) characterized by a combination of increase